Integrated Investment Consultants LLC Cuts Stake in Johnson & Johnson $JNJ

Integrated Investment Consultants LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 25.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 8,249 shares of the company’s stock after selling 2,772 shares during the quarter. Integrated Investment Consultants LLC’s holdings in Johnson & Johnson were worth $1,260,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of JNJ. Brighton Jones LLC lifted its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the period. United Bank lifted its holdings in shares of Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after buying an additional 4,876 shares during the period. Maia Wealth LLC boosted its stake in shares of Johnson & Johnson by 10.3% in the 1st quarter. Maia Wealth LLC now owns 2,812 shares of the company’s stock worth $434,000 after buying an additional 263 shares during the last quarter. Delos Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson by 3.2% in the first quarter. Delos Wealth Advisors LLC now owns 2,610 shares of the company’s stock worth $433,000 after acquiring an additional 80 shares during the period. Finally, Sustainable Insight Capital Management LLC lifted its holdings in Johnson & Johnson by 35.3% in the first quarter. Sustainable Insight Capital Management LLC now owns 2,300 shares of the company’s stock valued at $381,000 after acquiring an additional 600 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent research reports. Sanford C. Bernstein increased their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Johnson Rice set a $190.00 price target on Johnson & Johnson and gave the company a “hold” rating in a report on Wednesday, October 22nd. Finally, JPMorgan Chase & Co. raised their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 16th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $203.15.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $199.99 on Wednesday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $207.81. The stock’s 50-day simple moving average is $194.74 and its 200-day simple moving average is $176.23. The company has a market capitalization of $481.82 billion, a price-to-earnings ratio of 19.30, a PEG ratio of 2.25 and a beta of 0.36.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. As a group, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.